News | Breast Imaging | September 03, 2020

Candelis Lauded for Accelerating Accurate Diagnosis with Its Multi-Modal Breast Imaging Solution

The solution leverages image transfer speed, tag morphing, and multi-vendor PACS capabilities to enable comprehensive image visualization and analysis at the point of care

The solution leverages image transfer speed, tag morphing, and multi-vendor PACS capabilities to enable comprehensive image visualization and analysis at the point of care

September 3, 2020 — Based on its recent analysis of the global breast imaging workstation industry, Frost & Sullivan recognized Candelis, Inc. with the 2020 Global New Product Innovation Award for its Advanced Breast Imaging Enterprises Viewer. This breast imaging workstation incorporates unique optimization techniques for streamlining clinical workflows, enabling patient-centric direct scan visualization and interpretation, and enhancing the patient experience by delivering immediate results. Its pre-fetching, tag morphing, and multi-modal capabilities deliver unmatched data movement and routing speeds, giving radiologists access to all the information needed for a timely and accurate read. The Advanced Breast Imaging Enterprises Viewer supports reading of 2-D and 3-D mammography along with 2-D and 3-D breast ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT).

"Candelis launched the Advanced Breast Imaging Enterprise Viewer with its flagship ImageGrid platform, providing exceptional speed and multi-vendor viewing. It displays past and present mammography and tomosynthesis patient images from leading OEMs almost instantly, regardless of scan format," said Poornima Srinivasan, industry analyst. "With enhanced pre-fetching capabilities, hospitals can view all mammography and tomosynthesis exams from any radiologist workstation and they have the necessary prior exam data before the patient comes in for a breast examination."

Many competing mammography solutions require data transfer to each workstation, increasing the strain on the hospital's IT networks. Candelis’ Advanced Breast Imaging Enterprise Viewer, in contrast, moves the data only once to the ImageGrid PACS, minimizing data duplication sent through the network. Furthermore, provision of rapid results means if the radiologist feels the patient needs additional examinations, an ultrasound or biopsy can be performed during the same visit. As for the customers, the streamlined, optimized workflows enhance their overall hospital experience.

Candelis supports its customers whenever and wherever needed, either on-site or via phone-support teams in Southern California and Western EU. Beyond high-quality support services, Candelis commits to tailoring innovation to match industry needs. It partners with customers within the breast imaging space to identify optimization gaps and continuously improve its products. These customer-driven innovation methods have earned it expertise in the IT data movement workflow area and keep it at the forefront of innovation.

"The company currently has over 3,700 customers worldwide using its ImageGrid System and anticipates increased uptake of the solution due to the market shift towards tomosynthesis," noted Srinivasan. "Besides its installations in Latin America, Southeast Asia, Western EU, and Canada, Candelis is working with the Brazilian and Japanese governments to gain approval and widen its market reach. Its significant footprint, customer-focused growth strategies, and cutting-edge innovation are expected to help the company continue expanding its customer base and remain a dominant player in the global market."

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased return on investment (ROI) it gives customers, which, in turn, raises customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

For more information: www.candelis.com

Related Content

MRI of Nonferromagnetic Ballistics Suspended in Gelatin. 

MRI of Nonferromagnetic Ballistics Suspended in Gelatin. Scout (A), T1-weighted spin-echo (SE) (B), T2-weighted SE (C), T2-weighted gradient-recalled echo (GRE) (TR/TE, 500/10; D), and T2-weighted GRE (TR/TE, 700/30; E) MR images show jacket hollow point .45 automatic Colt pistol bullet (Corbon) (1), solid lead .45 Long Colt bullet (Winchester) (2), full metal jacket (FMJ) automatic Colt pistol bullet (Winchester) (3), 5.56-mm FMJ bullet (Federal Ammunition) (4), #7 lead shotgun pellet (Winchester) (5), and 5-mm lead air gun pellet (Sheridan) (6). On all sequences, metallic artifact is minimal. Although metallic artifact increases or blooms with increased TR/TE in GRE images (D and E), amount of surrounding distortion is still minimal.

News | Magnetic Resonance Imaging (MRI) | January 15, 2021
January 15, 2021 — 
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
The U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency's oversight of AI/ML-based medical software.
News | Artificial Intelligence | January 12, 2021
January 12, 2021 — The U.S.
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...